Related Experiment Video

Updated: Apr 5, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

11.1K

Effect of montelukast monotherapy on oxidative stress parameters and DNA damage in children with asthma

Fatih Dilek1, Emin Ozkaya, Abdurrahim Kocyigit

  • 1Divisions of Pediatric Allergy and Immunology, Department of Pediatrics, Bezmialem Vakif University Medical Faculty, Istanbul, Turkey.

International Archives of Allergy and Immunology
|August 26, 2015
PubMed
Abstract

Insights

Montelukast monotherapy showed minimal impact on oxidative stress and DNA damage in pediatric asthma patients. While some parameters slightly improved, the changes were not statistically significant compared to untreated patients.

Area of Science:

  • Pediatric Pulmonology
  • Biochemistry
  • Molecular Biology

Background:

  • Oxidative stress is implicated in asthma pathogenesis.
  • Reactive oxygen species can cause DNA strand breaks.
  • Understanding treatment effects on these markers is crucial.

Purpose of the Study:

  • To investigate the effect of montelukast monotherapy on oxidative stress and DNA damage in children with asthma.
  • To compare oxidative stress and DNA damage markers between untreated asthmatic children, montelukast-treated children, and healthy controls.

Main Methods:

  • Plasma total oxidant status (TOS) and total antioxidant status (TAS) were measured.
  • DNA damage was assessed using the alkaline comet assay.
  • Study included newly diagnosed asthmatics, montelukast-treated asthmatics, and healthy controls.

Main Results:

  • Asthmatic patients (both groups) exhibited significantly higher TOS and lower TAS than controls.
  • DNA damage was significantly higher in untreated asthmatic patients compared to controls.
  • Montelukast-treated patients showed no statistically significant improvement in TOS, TAS, or DNA damage compared to untreated patients.

Conclusions:

  • Montelukast monotherapy demonstrated a minimal, non-statistically significant effect on oxidative stress and DNA damage markers in pediatric asthma.
  • Further research may be needed to explore the therapeutic potential of montelukast concerning oxidative stress and DNA damage in asthma.

More Related Videos

Quantification of three DNA Lesions by Mass Spectrometry and Assessment of Their Levels in Tissues of Mice Exposed to Ambient Fine Particulate Matter12:15

Quantification of three DNA Lesions by Mass Spectrometry and Assessment of Their Levels in Tissues of Mice Exposed to Ambient Fine Particulate Matter

Published on: May 29, 2019

9.3K
Comet Assay as an Indirect Measure of Systemic Oxidative Stress08:23

Comet Assay as an Indirect Measure of Systemic Oxidative Stress

Published on: May 22, 2015

30.1K

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.9K
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.7K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K